Financial Performance - Net income for Q1 2025 was $43.1 million, with a basic net income per share of $5.12, compared to a net loss of $34.9 million in Q1 2024[6]. - The change in fair value of common warrants resulted in income of $61.5 million for Q1 2025, compared to a loss of $14.4 million in Q1 2024[11]. - Cash, cash equivalents, and investments totaled $137.9 million as of March 31, 2025, up from $56.9 million as of December 31, 2024, providing funding into the second half of 2026[5]. - Total liabilities decreased to $34.3 million as of March 31, 2025, from $99.1 million as of December 31, 2024[18]. Research and Development - Aligos raised over $100 million to initiate a Phase 2 study of ALG-000184 for chronic hepatitis B virus infection, with dosing expected to begin by mid-2025[2]. - Research and development expenses decreased to $14.5 million in Q1 2025 from $16.4 million in Q1 2024, primarily due to reduced clinical trial costs[7]. - ALG-000184 demonstrated 100% sustained HBV DNA suppression in HBeAg subjects after 48 weeks of treatment[3]. - The Phase 2 B-SUPREME study for ALG-000184 is expected to enroll approximately 200 untreated adult subjects with chronic HBV infection[3]. - ALG-055009 showed statistically significant liver fat reductions of up to 46.2% at week 12 in MASH patients, with 70% of subjects achieving a ≥30% relative reduction[10]. Operating Expenses - General and administrative expenses fell to $5.1 million in Q1 2025 from $6.7 million in Q1 2024, attributed to lower third-party expenses[8].
Aligos Therapeutics(ALGS) - 2025 Q1 - Quarterly Results